Toggle sidebar
定价
登录
Experimental melanoma drug
搜索文档
Replimune Gets Third Try at FDA Approval After Makary Departure
WSJ
·
2026-05-29 19:30
药物研发与监管审批 - 一款实验性黑色素瘤药物因其研究设计受到美国食品药品监督管理局的质疑而两次被拒绝[1]
Replimune(US:REPL)
Pharmaceuticals
Experimental melanoma drug
Pharmaceuticals
Experimental melanoma drug